Therapeutic targeting with an anti-osteopontin antibody improved BBB function that reduced cerebral edema, the risk for hemorrhagic transformation and improved neurological outcome in a mouse model of ischemic stroke. The gene discussed is SPP1; the disease is ischemic stroke.